Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Are Drug-Drug Interactions Today’s Biggest Health Threat?

Posted on October 16th, 2018 by in Pharma R&D

The use of prescription medicines is sharply on the rise. Over the past decade, the number of adults taking over-the-counter medicines has sunk, while the number of prescription drug users has increased by more than 30 percent. Continue reading “Are Drug-Drug Interactions Today’s Biggest Health Threat?” »

Reducing Adverse Event Risk

Posted on September 25th, 2017 by in Pharma R&D

In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” Continue reading “Reducing Adverse Event Risk” »

Assessing DDI Risk in the Digital Age

Posted on August 9th, 2017 by in Pharmacovigilance

pills pic for SD case study
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”

Continue reading “Assessing DDI Risk in the Digital Age” »